Substituted [1H-imidazol-5-ylialkanoic acids having angiotension II
申请人:SmithKline Beecham Corporation
公开号:US05444080A1
公开(公告)日:1995-08-22
Angiotensin II receptor antagonists having the formula: ##STR1## which are useful in regulating hypertension and in the treatment of congestive heart failure, renal failure, and glaucoma, pharmaceutical compositions including these antagonists, and methods of using these compounds to produce angiotensin II receptor antagonism in mammals.
This invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier, an angiotensin II receptor antagonist and a second agent selected from a diuretic, a calcium channel blocker, a .beta.-adrenoceptor blocker, a renin inhibitor, or an angiotensin converting enzyme inhibitor and a method of treating hypertension.
Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
申请人:SmithKline Beecham Corporation
公开号:US05185351A1
公开(公告)日:1993-02-09
Angiotensin II receptor antagonists having the formula: ##STR1## which are useful in regulating hypertension and in the treatment of congestive heart failure, renal failure, and glaucoma, pharmaceutical compositions including these antagonists, and methods of using these compounds to produce angiotensin II receptor antagonism in mammals.
Substituted 5-((tetrazolyl)alkenyl)imidazoles and pharmaceutical methods
申请人:SmithKline Beecham Corporation
公开号:US05177096A1
公开(公告)日:1993-01-05
Angiotensin II receptor antagonists having the formula: ##STR1## which are useful in regulating hypertension and in the treatment of congestive heart failure, renal failure, and glaucoma, pharmaceutical compositions including these antagonists, and methods of using these compounds to produce angiotensin II receptor antagonism in mammals.
[EN] USE OF ANGIOTENSIN II ANTAGONIST IN THE TREATMENT OF INFARCTION
申请人:SMITHKLINE BEECHAM PLC
公开号:WO1992010180A1
公开(公告)日:1992-06-25
(EN) The present invention relates to the use of an angiotensin II receptor antagonist in the manufacture of a medicament for primary and secondary prevention of infarction.(FR) L'invention se rapporte à l'utilisation d'un agent, antagoniste du récepteur de l'angiotensine II dans la fabrication d'un médicament destiné à la prévention primaire et secondaire des infarctus.